Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma

被引：0
|
作者：
Thomas Powles
Robert J. Motzer
Bernard Escudier
Sumanta Pal
Christian Kollmannsberger
Joanna Pikiel
Howard Gurney
Sun Young Rha
Se Hoon Park
Poul F. Geertsen
Marine Gross-Goupil
Enrique Grande
Cristina Suarez
David W. Markby
Alan Arroyo
Mark Dean
Toni K. Choueiri
Daniel George
机构：
[1] University of London,Barts Cancer Institute, Cancer Research UK Experimental Cancer Medicine Centre, Queen Mary University of London, Royal Free NHS Trust, Queen Mary
[2] Memorial Sloan Kettering Cancer Center,British Columbia Cancer Agency
[3] Gustave Roussy,Macquarie University and Westmead Hospital
[4] City of Hope National Medical Center,Severance Hospital
[5] BCCA Vancouver Cancer Centre,Herlev and Gentofte Hospital, Herlev Hospital
[6] Wojewodzkie Centrum Onkologii,Vall d’Hebron University Hospital and Institute of Oncology
[7] Macquarie University,undefined
[8] Yonsei Cancer Center,undefined
[9] Samsung Medical Center,undefined
[10] Copenhagen University,undefined
[11] Groupe Hospitalier Saint André,undefined
[12] Hospital Universitario Ramón y Cajal,undefined
[13] Universitat Autònoma de Barcelona,undefined
[14] Exelixis,undefined
[15] Inc,undefined
[16] Dana-Farber Cancer Institute,undefined
[17] Duke University Medical Center,undefined
来源：
British Journal of Cancer | 2018年 / 119卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：663 / 669
页数：6
相关论文
共 50 条
  • [1] Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma
    Powles, Thomas
    Motzer, Robert J.
    Escudier, Bernard
    Par, Sumanta
    Kollmannsberger, Christian
    Pikiel, Joanna
    Gurney, Howard
    Rha, Sun Young
    Park, Se Hoon
    Geertsen, Poul F.
    Gross-Goupil, Marine
    Grande, Enrique
    Suarez, Cristina
    Markby, David W.
    Arroyo, Alan
    Dean, Mark
    Choueiri, Toni K.
    George, Daniel
    BRITISH JOURNAL OF CANCER, 2018, 119 (06) : 663 - 669
  • [2] Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma
    Donskov, Frede
    Motzer, Robert J.
    Voog, Eric
    Hovey, Elizabeth
    Gruellich, Carsten
    Nott, Louise M.
    Cuff, Katharine
    Gil, Thierry
    Jensen, Niels Viggo
    Chevreau, Christine
    Negrier, Sylvie
    Depenbusch, Reinhard
    Bergmann, Lothar
    Cornelio, Izzy
    Champsaur, Anne
    Escudier, Bernard
    Pal, Sumanta
    Powles, Thomas
    Choueiri, Toni K.
    EUROPEAN JOURNAL OF CANCER, 2020, 126 : 1 - 10
  • [3] Cabozantinib versus everolimus in patients with advanced renal cell carcinoma: Results of the randomized phase 3 METEOR trial
    Choueiri, T.
    Escudier, B.
    Powles, T.
    Mainwaring, P.
    Rini, B.
    Donskov, F.
    Hammers, H.
    Hutson, T.
    Roth, B.
    Peltola, K.
    Lee, J. L.
    Heng, D.
    Schmidinger, M.
    Borgman-Hagey, A.
    Hessel, C.
    Scheffold, C.
    Schwab, G.
    Tannir, N.
    Motzer, R.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S708 - S709
  • [4] Outcomes based on age in the phase 3 METEOR trial of cabozantinib (cabo) versus everolimus (eve) in patients with advanced renal cell carcinoma (RCC).
    Donskov, Frede
    Motzer, Robert J.
    Voog, Eric
    Hovey, Elizabeth J.
    Grullich, Carsten
    Nott, Louise M.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [5] Clinical Outcomes by Nephrectomy Status In METEOR, A Randomized Phase 3 Trial of Cabozantinib Versus Everolimus in Patients with Advanced Renal Cell Carcinoma
    Tannir, Nizar M.
    Powles, Thomas
    Escudier, Bernard
    Donskov, Frede
    Gruenwald, Viktor
    Sternberg, Cora N.
    Schmidinger, Manuela
    Schoeffski, Patrick
    Szczylik, Cezary
    Peltolta, Katriina
    Nosov, Dmitry
    Melichar, Bohuslav
    Clary, Douglas
    Scheffold, Christian
    Motzer, Robert J.
    Choueiri, Toni K.
    KIDNEY CANCER, 2020, 4 (01) : 29 - 39
  • [6] Clinical outcomes based on MET expression level in METEOR, a randomized phase 3 trial of cabozantinib versus everolimus in advanced renal cell carcinoma (RCC)
    Powles, Thomas
    Escudier, Bernard
    Motzer, Robert J.
    Tannir, Nizar M.
    Scheffold, Christian
    Aftab, Dana T.
    Chouieri, Toni K.
    BJU INTERNATIONAL, 2016, 118 : 4 - 4
  • [7] Correction to: Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma
    Thomas Powles
    Toni K. Choueiri
    Robert J. Motzer
    Eric Jonasch
    Sumanta Pal
    Nizar M. Tannir
    Sabina Signoretti
    Rajesh Kaldate
    Christian Scheffold
    Evelyn Wang
    Dana T. Aftab
    Bernard Escudier
    Daniel J. George
    BMC Cancer, 21
  • [8] METEOR: results from the randomized phase 3 trial of cabozantinib versus everolimus in pts with advanced renal cell carcinoma (RCC)
    Powles, Thomas
    Escudier, Bernard
    Mainwaring, Paul N.
    Rini, Brian I.
    Donskov, Frede
    Hammers, Hans J.
    Hutson, Thomas E.
    Roth, Bruce
    Peltola, Katriina
    Lee, Jae Lyun
    Heng, Daniel Y. C.
    Schmidinger, Manuela
    Borgman, Anne
    Hessel, Colin
    Scheffold, Christian
    Schwab, Gisela
    Tannir, Nizar M.
    Motzer, Robert J.
    Choueiri, Toni K.
    BJU INTERNATIONAL, 2015, 116 : 19 - 19
  • [9] Effect of prior systemic therapy on clinical outcomes with cabozantinib vs everolimus in advanced renal cell carcinoma: Results from the phase 3 METEOR study
    Grande, E.
    Choueiri, T. K.
    Motzer, R. J.
    Escudier, B.
    Pal, S.
    Kollmannsberger, C.
    Pikiel, J.
    Gurney, H.
    Rha, S. Y.
    Park, S. H.
    Geertsen, P. F.
    Goupil, M. Gross
    Suarez, C.
    Arroyo, A.
    Dean, M.
    George, D.
    Powles, T.
    EUROPEAN JOURNAL OF CANCER, 2017, 72 : S197 - S198
  • [10] Outcomes based on age in the phase 3 METEOR trial of cabozantinib (cabo) vs everolimus (eve) in patients with advanced renal cell carcinoma (RCC).
    Donskov, Frede
    Motzer, Robert J.
    Voog, Eric
    Hovey, Elizabeth J.
    Griillich, Carsten
    Nott, Louise M.
    Cuff, Katharine Ellen
    Gil, Thierry
    Jensen, Niels Viggo
    Chevreau, Christine
    Negrier, Sylvie
    Depenbusch, Reinhard
    Bergmann, Lothar
    Cornelio, Izzy
    Champsaur, Anne
    Escudier, Bernard J.
    Pal, Sumanta K.
    Powles, Thomas
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345